ストックスクリーナーアプリを入手
2.81
0.71%
-0.02
前日終値:
$2.83
開ける：
$2.89
24時間の取引高:
572.75K
Relative Volume:
0.42
時価総額：
$299.53M
収益：
-
当期純損益:
$-134.24M
株価収益率:
-1.5876
EPS:
-1.77
ネットキャッシュフロー:
$-121.34M
1週間 パフォーマンス:
-8.47%
1か月 パフォーマンス:
-32.61%
6か月 パフォーマンス:
-52.45%
1年 パフォーマンス:
-42.77%
1日の値動き範囲:
$2.78
$2.93
1週間の範囲:
$2.635
$3.17
52週間の値動き範囲:
$2.635
$8.40
Annexon Inc Stock (ANNX) Company Profile
ANNX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
2.81 | 299.53M | 0 | -134.24M | -121.34M | -1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Annexon Inc Stock (ANNX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-03-01 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-12-21 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-10-30 | 開始されました | Wells Fargo | Overweight |
| 2023-05-26 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-05-25 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-09-16 | 開始されました | Jefferies | Buy |
| 2022-09-09 | 開始されました | BTIG Research | Buy |
| 2021-11-30 | 開始されました | H.C. Wainwright | Buy |
| 2021-09-23 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-01-26 | 開始されました | Needham | Buy |
| 2020-08-18 | 開始されました | BofA Securities | Buy |
| 2020-08-18 | 開始されました | Cowen | Outperform |
| 2020-08-18 | 開始されました | JP Morgan | Overweight |
すべてを表示
Annexon Inc (ANNX) 最新ニュース
Annexon executive sells shares worth $16,379 By Investing.com - Investing.com South Africa
Annexon chief medical officer sells $16,342 in common stock - Investing.com
Annexon EVP Ted Yednock sells $24,283 in stock - Investing.com
Annexon executive sells shares worth $16,379 - Investing.com
Annexon chief business officer sells $19,523 in company stock - Investing.com
Annexon EVP Ted Yednock sells $24,283 in stock By Investing.com - Investing.com South Africa
Annexon CFO Jennifer Lew sells shares worth $20,183 By Investing.com - Investing.com South Africa
Annexon CFO Jennifer Lew sells shares worth $20,183 - Investing.com
Annexon chief medical officer sells $16,342 in common stock By Investing.com - Investing.com UK
Annexon CFO Jennifer Lew Sells Shares to Cover Tax Obligations - TradingView
Annexon, Inc. (NASDAQ:ANNX) Short Interest Update - MarketBeat
Annexon, Inc. (NASDAQ:ANNX) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Douglas Love Sells 5,021 Shares of Annexon, Inc. (NASDAQ:ANNX) Stock - MarketBeat
Annexon EVP sells $4,260 in stock to cover tax obligations By Investing.com - Investing.com Canada
Annexon EVP Ted Yednock sells $5,331 in stock By Investing.com - Investing.com Canada
Annexon CFO Jennifer Lew sells $5,322 in stock By Investing.com - Investing.com South Africa
Annexon EVP sells $4,260 in stock to cover tax obligations - Investing.com India
Annexon CFO Jennifer Lew sells $5,322 in stock - Investing.com India
Annexon CEO Love Douglas sells $14,811 in stock By Investing.com - Investing.com South Africa
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Employee Stock Options Alert: Annexon Awards Major Equity Package Worth $1.6M - StockTitan
Annexon stock hits 52-week low at $3.04 amid market challenges - MSN
Annexon, Inc. (NASDAQ:ANNX) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Form 8-KCurrent report - br.ADVFN.com
Annexon's ANX007 Shows Significant Retinal Protection In Geographic Atrophy In Phase 2 Trial - Nasdaq
A look into Annexon Inc (ANNX)’s deeper side - SETE News
Annexon Announces Presentations Highlighting ANX007 - GlobeNewswire
Annexon Inc (NASDAQ: ANNX) Slashes -3.54%: What Could Be On The Way Going Forward? - Stocks Register
Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting - GlobeNewswire
Revolutionary Eye Treatment ANX007 Preserves Vision in Geographic Atrophy Patients: Clinical Data Revealed - StockTitan
Critical Survey: Prothena (NASDAQ:PRTA) vs. Annexon (NASDAQ:ANNX) - Defense World
A stock that deserves closer examination: Annexon Inc (ANNX) - US Post News
Annexon Inc (ANNX) Shares Decline Despite Market Challenges - The News Heater
Check out these key findings about Annexon Inc (ANNX) - SETE News
Annexon Inc [ANNX] Investment Guide: What You Need to Know - Knox Daily
A year in review: Annexon Inc (ANNX)’s performance in the last year - US Post News
Market Update: Annexon Inc (ANNX) Sees Negative Movement, Closing at 3.52 - The Dwinnex
Analyzing the Impact of Earnings Reports on Annexon Inc Inc. (ANNX) Price Performance - The InvestChronicle
Annexon, Inc. (NASDAQ:ANNX) Short Interest Up 23.7% in January - MarketBeat
Annexon (NASDAQ:ANNX) and Tonix Pharmaceuticals (NASDAQ:TNXP) Head-To-Head Comparison - Defense World
What's Driving These Stocks Higher In After-hours? - RTTNews
Vanguard Group Inc's Strategic Acquisition of Annexon Inc Shares - GuruFocus.com
Annexon stock touches 52-week low at $3.85 amid market challenges - Investing.com Australia
Critical Survey: Day One Biopharmaceuticals (NASDAQ:DAWN) vs. Annexon (NASDAQ:ANNX) - Defense World
Annexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals - MSN
Cantor Fitzgerald Estimates Annexon FY2025 Earnings - Defense World
Annexon Inc (ANNX) 財務データ
収益
当期純利益
現金流量
EPS
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):